CONMED reported Q4 2025 EPS of $1.43, beating consensus of $1.32, with orthopedics revenue up 12.1% and supply chain backorders at a three-year low. Despite the operational beat, management guided 2026 EPS to $4.30-$4.45, down from $4.59, attributing the decline entirely to the GI portfolio exit ($0.45-$0.50 headwind) and tariff impacts ($0.30-$0.35).

The guidance reduction is mechanical, not operational. Organic growth is projected at 4.5-6%, reflecting continued momentum in the core orthopedics and AirSeal franchises. Management disclosed that AirSeal has achieved 6-7% penetration of a 3M+ annual procedure market, indicating substantial runway for further adoption.

The CFO departure adds governance uncertainty. The 8-K filing language indicates termination rather than voluntary separation, though no accounting or financial disagreement was disclosed. The new CEO, in place for one year, is executing a portfolio rationalization strategy.

Management suspended the dividend and announced a $150M share buyback program, representing approximately 14% of current market capitalization. Leverage is declining to 2.9x, and the company signaled appetite for M&A in its focused categories.

The evidence mix is mildly bearish near-term due to the guidance step-down and CFO departure, but the underlying operational performance remains strong. Supply chain normalization and AirSeal's early-stage penetration curve are structural positives. The market is reacting to headline EPS decline without distinguishing between one-time portfolio exits and core business trajectory.

Q4 marks the fourth consecutive earnings beat (17%, 2.4%, 2.7%, 8%). The company is guiding to mid-single-digit organic growth despite exiting a business segment and facing tariff headwinds. AirSeal's 6-7% penetration of 3M+ procedures represents a material long-duration growth driver in a large addressable market.